Published in Curr Opin HIV AIDS on January 01, 2011
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis (2014) 1.89
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis (2012) 1.72
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Snapshots: chromatin control of viral infection. Virology (2013) 1.39
Developing strategies for HIV-1 eradication. Trends Immunol (2012) 1.38
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A (2012) 1.19
HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int (2011) 1.09
Global Promoter Targeting of a Conserved Lysine Deacetylase for Transcriptional Shutoff during Quiescence Entry. Mol Cell (2015) 1.04
Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity (2014) 0.99
Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics (2015) 0.98
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11. Br J Pharmacol (2014) 0.94
An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. J Virol (2013) 0.94
Transcriptional regulation of latent feline immunodeficiency virus in peripheral CD4+ T-lymphocytes. Viruses (2012) 0.93
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
SIV replication is directly downregulated by four antiviral miRNAs. Retrovirology (2013) 0.89
Epigenetic regulation of HIV-1 latency in astrocytes. J Virol (2013) 0.89
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Mechanisms of HIV Transcriptional Regulation and Their Contribution to Latency. Mol Biol Int (2012) 0.86
Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. Virus Res (2012) 0.85
Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother (2013) 0.85
BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe (2015) 0.83
Feline immunodeficiency virus latency. Retrovirology (2013) 0.81
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Sci Rep (2015) 0.80
The Role of RNA Polymerase II Elongation Control in HIV-1 Gene Expression, Replication, and Latency. Genet Res Int (2011) 0.80
Dissecting the mechanism of histone deacetylase inhibitors to enhance the activity of zinc finger nucleases delivered by integrase-defective lentiviral vectors. Hum Gene Ther (2014) 0.79
Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages. Antimicrob Agents Chemother (2015) 0.78
Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats. J Vet Pharmacol Ther (2013) 0.78
A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism. Sci Rep (2015) 0.78
The effects of cocaine on HIV transcription. J Neurovirol (2015) 0.78
Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Clin Epigenetics (2016) 0.77
Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol (2012) 0.77
The future of HIV treatment. J Acquir Immune Defic Syndr (2012) 0.77
Interaction between endogenous bacterial flora and latent HIV infection. Clin Vaccine Immunol (2013) 0.77
Viral latency and potential eradication of HIV-1. Expert Rev Anti Infect Ther (2012) 0.77
Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid. Antiviral Res (2014) 0.77
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors. PLoS One (2016) 0.77
Verotoxin A subunit protects lymphocytes and T cell lines against X4 HIV infection in vitro. Toxins (Basel) (2012) 0.76
Medicinal chemistry: Forcing an enemy into the open. Nat Chem (2012) 0.75
HIV infection: what should be considered in approaches for a cure? AIDS (2012) 0.75
Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes. J Pers Nanomed (2015) 0.75
Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients? J Virus Erad (2015) 0.75
Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological Disorders: New Insights for Diagnosis and Therapeutic Applications. Viruses (2017) 0.75
Identification of benzazole compounds that induce HIV-1 transcription. PLoS One (2017) 0.75
Translating the histone code. Science (2001) 56.77
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol (2003) 5.92
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J (1996) 5.10
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J (1993) 3.95
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Transcriptional repression: the long and the short of it. Genes Dev (2001) 2.91
The presence of nucleosomes on a DNA template prevents initiation by RNA polymerase II in vitro. Cell (1986) 2.88
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog (2009) 2.50
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev (1997) 2.25
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J (2003) 2.02
DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol (1991) 1.90
Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem (2006) 1.73
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses (2009) 1.66
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep (2010) 1.33
Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology (1993) 1.27
Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res (2010) 1.25
The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr (2010) 1.22
Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med (2010) 1.04
Sodium butyrate activates human immunodeficiency virus long terminal repeat--directed expression. Biochem Biophys Res Commun (1987) 0.90
Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication. Virology (2010) 0.90